Use of placebo: Knowledge, attitude and practice among medical practitioners

Shah, Kartik; Panchal, Dhaval J.; Vyas, Bhavesh M; Patel, Varsha J.

doi:10.4103/0019-5359.57640

Cited by 16 publications

(24 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A number of studies reported that placebos are indeed used by clinicians across different countries (Fassler, Meissner, Schneider, & Linde, 2010; Kermen, Hickner, Brody, & Hasham, 2010; Louhiala, 2012; Meissner, Hofner, Fassler, & Linde, 2012; Nizan, Barash, Valinsky, Lichter, & Manulis, 1997; Tilburt, Emanuel, Kaptchuk, Curlin, & Miller, 2008) including United States (Kermen et al, 2010; Sherman & Hickner, 2008; Tilburt et al, 2008), Canada (Harris & Raz, 2012; Raz et al, 2011), Germany (Linde et al., 2013; Meissner, 2005), Switzerland (Fassler, Gnadinger, Rosemann, & Biller-Andorno, 2009), Denmark (Hrobjartsson & Norup, 2003), United Kingdom (Howick et al, 2013), Israel (Nitzan & Lichtenberg, 2004), India (Shah, Panchal, Vyas, & Patel, 2009), Saudi Arabia (Hassan, Fauzi, & Hasan, 2011), and New Zealand (Holt & Gilbey, 2009). A systematic review of 22 studies from 12 different countries reported that between 17% and 80% of interviewed clinicians administered sugar pills or saline injections during their careers (Fassler et al., 2010).…”

Section: Discussionmentioning

confidence: 99%

Placebos Without Deception: Outcomes, Mechanisms, and Ethics

Colloca

Howick

2018

International Review of Neurobiology

View full text Add to dashboard Cite

Scientific research indicates that open-label and dose-extending placebos (that patients know are placebos) can elicit behavioral, biological, and clinical outcome changes. In this chapter, we present the state-of-the-art evidence and ethical considerations about open-label and dose-extending placebos, discussing the perspective of giving placebos with a rational, as dose extension of active drugs, or expectancy boosters. Previous comprehensive reviews of placebo use have considered how to harness placebo effects in medicine and the need to focus on elements of the clinical encounter as well as patient–clinician relations. Here, we illustrate the similarities and differences between standard (deceptive) placebos, open-label placebos and dose-extending placebos. We conclude that placebos without deception would override ethical barriers to their clinical use. This paves the way to future large-scale, pragmatic randomized trials that investigate the potential of ethical open-label and dose-extending placebos to improve patients’ outcomes, and reduce side effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Placebos Without Deception: Outcomes, Mechanisms, and Ethics

Colloca

Howick

2018

International Review of Neurobiology

View full text Add to dashboard Cite

show abstract

“…In several surveys conducted among physicians, it appears that placebo use is common in clinical practice worldwide. [88][89][90] In a meta-analysis of twenty-two surveys from twelve countries, the proportion of physicians that use pure placebos (inert interventions) varied between 17% and 80%. The proportion of nurses using pure placebos varied between 51% and 100%.…”

Section: Discussionmentioning

confidence: 99%

Placebos in the era of open‐label trials: An update for clinicians

Sagy

Abres

Winnick

et al. 2018

Eur J Clin Investigation

View full text Add to dashboard Cite

Placebos have been used extensively by vast numbers of physicians, in a majority of clinical trials. Placebo effects involve behavioural, psychological and genetic factors and have been subject to ethical controversies stemming from the use of deception in treating patients. The patient‐physician encounter, endogenous pharmacological pathways, personality traits and genetic diversity have all been reported to be key players in placebo responses. In the last decade, a new methodological paradigm of placebo research has emerged, using open‐label placebos to investigate their effects which showed promising results for various common medical conditions. In this review, we will summarize the current body of evidence on placebos in clinical practice, with a view to open‐label placebo trials in particular. It is our view that future larger‐scale randomized blinded open placebo trials will benefit physicians and improve patient outcomes.

show abstract

“…Sir, I read the article "Use of placebo: knowledge, attitude and practice among medical practitioners" [1] with great interest. It is really commendable that authors have studied the use of placebo by medical practitioners in the Indian setup.…”

Section: The Placebo Therapymentioning

confidence: 99%

The placebo therapy

Aggarwal

2009

Indian J Med Sci

View full text Add to dashboard Cite

Use of placebo: Knowledge, attitude and practice among medical practitioners

Cited by 16 publications

References 4 publications

Placebos Without Deception: Outcomes, Mechanisms, and Ethics

Placebos Without Deception: Outcomes, Mechanisms, and Ethics

Placebos in the era of open‐label trials: An update for clinicians

The placebo therapy

Contact Info

Product

Resources

About